

Notice Regarding Change in Major Shareholder and Largest Shareholder

Tokyo, Japan and Cambridge, UK, 5 December 2025 – Nxera Pharma Co. Ltd (“Nxera” or “the Company; TSE 4565) announces that, as of 27 November 2025, there has been a change in the major shareholder and the largest shareholder of the Company.

1. Background behind the change

As of 4 December 2025, the Company confirmed a change in its major shareholder and its largest shareholder, following the submission of a Report of Possession of Large Volume (Change Report No.7) to the Kanto Local Finance Bureau.

2. Overview of the shareholder

(1) Name	Daisuke Gomi
(2) Address	Matsumoto, Nagano

3. Number of shares held, number of voting rights, and percentage of voting rights for the shareholder before and after the change

	Number of voting rights held (Number of shares)	Percentage of voting rights	Major shareholder ranking
Before the change	67,200 voting rights (6,720,000 shares)	7.43%	2nd
After the change	96,250 voting rights (9,625,000 shares)	10.64%	1st

Note 1: Percentage of voting rights is calculated based on the total number of issued shares (90,496,735) and the total number of voting rights of all shareholders (904,408) as of 30 June 2025. The number of shares that do not have voting rights as of 30 June 2025 is 55,935 shares.

Note 2: The above information is based on the Report of Possession of Large Volume (Change Report) submitted by the shareholder. The Company has not been able to confirm the number of shares actually held in the name of the shareholder.

4. Future outlook

There is nothing to be noted.

–END–

About Nxera Pharma

Nxera Pharma is a technology powered biopharma company in pursuit of new specialty medicines to improve the lives of patients with unmet needs in Japan and globally.

We have built an agile, new-generation commercial business in Japan to develop and commercialize innovative medicines, including several launched products, to address this high value, large and growing market and those in the broader APAC region.

Behind that, and powered by our unique NxWave™ discovery platform, we are advancing an extensive pipeline of over 30 active programs from discovery through to late clinical stage internally and in partnership with leading pharma and biotech companies. This pipeline of potentially first- and best-in-class candidates is focused on addressing major unmet needs in some of the fastest-growing areas of medicine across obesity and metabolic disorders, neurology/neuropsychiatry and immunology and inflammation.

Nxera employs approximately 400 talented people at key locations in Tokyo and Osaka (Japan), London and Cambridge (UK), Basel (Switzerland) and Seoul (South Korea) and is listed on the Tokyo Stock Exchange (ticker: 4565).

For more information, please visit www.nxera.life

LinkedIn: [@NxeraPharma](#) | X: [@NxeraPharma](#) | YouTube: [@NxeraPharma](#)

Enquiries:

Media and Investor Relations

Shinya Tsuzuki, VP, Head of Investor Relations

Shinichiro Nishishita, VP Investor Relations, Head of Regulatory Disclosures

Maya Bennison, Communications Manager

+81 (0)3 5962 5718 | +44 (0)1223 949390 | IR@Nxera.life

MEDiSTRAVA (for International Media)

Mark Swallow, Frazer Hall, Erica Hollingsworth

+44 (0)203 928 6900 | Nxera@medistrava.com

Forward-looking statements

This press release contains forward-looking statements, including statements about the discovery, development, and commercialization of products. Various risks may cause Nxera Pharma Group's actual results to differ materially from those expressed or implied by the forward looking statements, including: adverse results in clinical development programs; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialize products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialization activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.